AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37400844 — intervention group
Group type: EXPERIMENTAL
Intervention: FCN-159 8 mg
Number of subjects: 19
Study 37400844 — intervention group
Group type: EXPERIMENTAL
Intervention: FCN-159 12 mg
Number of subjects: 19
Study 37400844 — intervention group
Group type: EXPERIMENTAL
Intervention: FCN-159 (all doses)
Number of subjects: 19
Study 37400849 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin infiltration treatment (Icon®) applied to hypomineralised enamel lesions
Number of subjects: 37
Study 37400849 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin infiltration treatment (Icon®)
Number of subjects: 37
Study 37400931 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron treatment
Number of subjects: 20
Study 37401127 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal pinch strength in men
Number of subjects: 0
Study 37401127 — intervention group
Group type: COMPARATOR
Intervention: Key pinch
Number of subjects: 0
Study 37401127 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmar pinch
Number of subjects: 0
Study 37401394 — intervention group
Group type: EXPERIMENTAL
Intervention: Competing stroke etiologies (including large-artery atherosclerosis)
Number of subjects: 907
Study 37401394 — intervention group
Group type: COMPARATOR
Intervention: Cardioembolism as the only plausible etiology
Number of subjects: 907
Study 37401479 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled Epoprostenol (iEPO)
Number of subjects: 231
Study 37401479 — intervention group
Group type: COMPARATOR
Intervention: Nitric Oxide (iNO)
Number of subjects: 231
Study 37401523 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan (Sac/Val)
Number of subjects: 420
Study 37401523 — intervention group
Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 420
Study 37401618 — intervention group
Group type: EXPERIMENTAL
Intervention: MPV-4 (quadrivalent meningococcal polysaccharide vaccine)
Number of subjects: 260
Study 37401618 — intervention group
Group type: COMPARATOR
Intervention: MCV-4 (quadrivalent meningococcal conjugate vaccine, Menactra®)
Number of subjects: 260
Study 37401618 — intervention group
Group type: EXPERIMENTAL
Intervention: MPV-4
Number of subjects: 260
Study 37401618 — intervention group
Group type: COMPARATOR
Intervention: MCV-4
Number of subjects: 260
Study 37401774 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG (re)vaccination
Number of subjects: 574
Study 37401774 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 antibodies
Number of subjects: 574
Study 37401774 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 or influenza vaccination
Number of subjects: 574
Study 37401774 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection pressure from COVID-19 pandemic waves
Number of subjects: 574
Study 37401774 — intervention group
Group type: EXPERIMENTAL
Intervention: Model diagnostics over calendar-time
Number of subjects: 574
Study 37401993 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-encapsulated antiretrovirals (ARVs) with ingestible sensor (IS) pills from baseline through week 16.
Number of subjects: 112
Study 37401993 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 112
Study 37402024 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal esketamine (56 mg) after pretreatment with nasal oxymetazoline (0.05%)
Number of subjects: 0
Study 37402024 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal esketamine (56 mg) after 16 consecutive days of mometasone (200 µg)
Number of subjects: 0
Study 37402024 — intervention group
Group type: COMPARATOR
Intervention: Nasal esketamine (56 mg)
Number of subjects: 0
Study 37402092 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO grade I meningioma
Number of subjects: 115
Study 37402092 — intervention group
Group type: COMPARATOR
Intervention: WHO grade II meningioma
Number of subjects: 115
Study 37402092 — intervention group
Group type: EXPERIMENTAL
Intervention: NF2-associated meningioma
Number of subjects: 115
Study 37402092 — intervention group
Group type: EXPERIMENTAL
Intervention: Sporadic meningioma
Number of subjects: 115
Study 37402092 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 115
Study 37402144 — intervention group
Group type: EXPERIMENTAL
Intervention: THRIVE intervention (cognitive behavioral app used daily over 21 days with weekly telephone coaching)
Number of subjects: 20
Study 37402144 — intervention group
Group type: EXPERIMENTAL
Intervention: THRIVE intervention
Number of subjects: 20
Study 37402153 — intervention group
Group type: EXPERIMENTAL
Intervention: ViTT vaccine
Number of subjects: 0
Study 37402153 — intervention group
Group type: EXPERIMENTAL
Intervention: ViPS vaccine
Number of subjects: 0
Study 37402153 — intervention group
Group type: COMPARATOR
Intervention: Control meningococcal vaccine
Number of subjects: 0
Study 37402275 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 1157
Study 37402281 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for vulvovaginal discomfort
Number of subjects: 302
Study 37402471 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual oral metronomic vinorelbine and capecitabine (mNC) regimen: oral vinorelbine (VNR) 40 mg three times weekly and capecitabine (CAP) 500 mg three times a day
Number of subjects: 29
Study 37402471 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual oral metronomic vinorelbine and capecitabine (mNC) regimen
Number of subjects: 29
Study 37402747 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone for 12 weeks
Number of subjects: 0
Study 37402852 — intervention group
Group type: EXPERIMENTAL
Intervention: Anhedonia severity and neural reward responsiveness (Reward Positivity amplitude, dorsal anterior cingulate cortex activation)
Number of subjects: 112
Study 37402852 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased neural reward responsiveness at baseline
Number of subjects: 112
Study 37402852 — intervention group
Group type: EXPERIMENTAL
Intervention: Differences in quality of life between unipolar and bipolar mood disorders
Number of subjects: 112
Study 37402852 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatments improving anhedonia and normalizing brain reward function
Number of subjects: 112
Study 37402864 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone-exposed children (n=98)
Number of subjects: 144
Study 37402864 — intervention group
Group type: COMPARATOR
Intervention: Comparison children (n=46)
Number of subjects: 144
Study 37402864 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone-exposed children with pharmacological treatment for NAS/NOWS (n=47)
Number of subjects: 144
Study 37402864 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone-exposed children without pharmacological treatment for NAS/NOWS (n=51)
Number of subjects: 144
Study 37403057 — intervention group
Group type: EXPERIMENTAL
Intervention: MAPS+ (6 proactive MAPS-based counseling calls over 12 months plus a 24-month digital treatment adjuvant)
Number of subjects: 340
Study 37403057 — intervention group
Group type: COMPARATOR
Intervention: Standard Treatment (ST)
Number of subjects: 340
Study 37403082 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting stress hyperglycemia ratio (SHR) in quartile 4
Number of subjects: 5308
Study 37403082 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose (FPG) in quartile 4
Number of subjects: 5308
Study 37403082 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting stress hyperglycemia ratio (SHR) as a continuous variable
Number of subjects: 5308
Study 37403082 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose (FPG) as a continuous variable
Number of subjects: 5308
Study 37403082 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting stress hyperglycemia ratio (SHR) and fasting plasma glucose (FPG)
Number of subjects: 5308
Study 37403082 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding fasting SHR or FPG to the original model
Number of subjects: 5308
Study 37403159 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose risperidone in combination with sertraline (RS group)
Number of subjects: 230
Study 37403159 — intervention group
Group type: COMPARATOR
Intervention: Regular-dose risperidone (control group)
Number of subjects: 230
Study 37403207 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve Gastrectomy (SG)
Number of subjects: 52
Study 37403207 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical controls (NS)
Number of subjects: 52
Study 37403248 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation-STakeholder Engagement Model (I-STEM)
Number of subjects: 55
Study 37403248 — intervention group
Group type: EXPERIMENTAL
Intervention: In-depth, semistructured interviews and observations
Number of subjects: 55
Study 37403255 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 cycles of rituximab (4R-CHOP+4R)
Number of subjects: 287
Study 37403255 — intervention group
Group type: COMPARATOR
Intervention: 6 cycles of R-CHOP plus 2 cycles of rituximab (6R-CHOP+2R)
Number of subjects: 287
Study 37403410 — intervention group
Group type: EXPERIMENTAL
Intervention: I-FABP
Number of subjects: 43
Study 37403410 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin-1
Number of subjects: 43
Study 37403410 — intervention group
Group type: EXPERIMENTAL
Intervention: L-lactate
Number of subjects: 43
Study 37403410 — intervention group
Group type: EXPERIMENTAL
Intervention: I-FABP + endothelin-1 combined
Number of subjects: 43
Study 37403610 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritlecitinib for 48 weeks
Number of subjects: 0
Study 37403610 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 24 weeks (followed by ritlecitinib for 24 weeks)
Number of subjects: 0
Study 37403652 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib plus nivolumab
Number of subjects: 311
Study 37403684 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive telerehabilitation with ReHub®
Number of subjects: 52
Study 37403684 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 52
Study 37404070 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib
Number of subjects: 0
Study 37404084 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-Based Staging
Number of subjects: 0
Study 37404084 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathologic Staging
Number of subjects: 0
Study 37404160 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg QD
Number of subjects: 450
Study 37404160 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg QD
Number of subjects: 450
Study 37404160 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Number of subjects: 450
Study 37404205 — intervention group
Group type: EXPERIMENTAL
Intervention: Faster Insulin Aspart
Number of subjects: 0
Study 37404205 — intervention group
Group type: COMPARATOR
Intervention: Standard Insulin Aspart
Number of subjects: 0
Study 37404855 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose n-3 (EPA + DHA) supplementation
Number of subjects: 0
Study 37404855 — intervention group
Group type: COMPARATOR
Intervention: High-dose n-6 (LA) supplementation
Number of subjects: 0
Study 37404971 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA-assisted therapy
Number of subjects: 0
Study 37404971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37405257 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-Oriented Attentional Self-Regulation (GOALS) training
Number of subjects: 0
Study 37405257 — intervention group
Group type: COMPARATOR
Intervention: Active control
Number of subjects: 0
Study 37405334 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon pulmonary angioplasty (BPA)
Number of subjects: 0
Study 37405334 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary endarterectomy
Number of subjects: 0
Study 37405334 — intervention group
Group type: COMPARATOR
Intervention: Vasodilator drugs
Number of subjects: 0
Study 37405406 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin
Number of subjects: 6692
Study 37405504 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative CT scan analyses with simple clinical and biological parameters
Number of subjects: 0
Study 37405504 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scan quantification
Number of subjects: 0
Study 37405504 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics analyses
Number of subjects: 0
Study 37405662 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-infective therapy along with a mixture of allografts with or without a collagen barrier membrane
Number of subjects: 33
Study 37405662 — intervention group
Group type: COMPARATOR
Intervention: Defect configuration (class 1B and 3B)
Number of subjects: 33
Study 37405710 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 6866
Study 37405746 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth utilization
Number of subjects: 0
Study 37405746 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 37405785 — intervention group
Group type: EXPERIMENTAL
Intervention: Fucoxanthin 12 mg once a day for 12 weeks
Number of subjects: 28
Study 37405785 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 37405821 — intervention group
Group type: EXPERIMENTAL
Intervention: Bracelet sensor tracking for real-time location and data collection
Number of subjects: 0
Study 37405821 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning for predicting surgery time based on historical data
Number of subjects: 0
Study 37405821 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation for evaluating system performance
Number of subjects: 0
Study 37405822 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive P300 speller task with personalized task difficulty adaptation
Number of subjects: 45
Study 37405822 — intervention group
Group type: COMPARATOR
Intervention: Adaptive P300 speller task with nonpersonalized task difficulty adaptation (Control Group 1)
Number of subjects: 45
Study 37405822 — intervention group
Group type: COMPARATOR
Intervention: Randomized task difficulty adaptation (Control Group 2)
Number of subjects: 45
Study 37405822 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback training through a P300 speller task
Number of subjects: 45
Study 37405844 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitally assisted peer recovery coach using the Lifeguard app
Number of subjects: 10
Study 37406026 — intervention group
Group type: EXPERIMENTAL
Intervention: Molehill Mountain app-based intervention
Number of subjects: 100
Study 37406106 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab, trastuzumab, and chemotherapy (PTC)
Number of subjects: 226
Study 37406106 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab
Number of subjects: 226
Study 37406180 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support (PS) intervention
Number of subjects: 12
Study 37406180 — intervention group
Group type: EXPERIMENTAL
Intervention: Community organization approach
Number of subjects: 12
Study 37406180 — intervention group
Group type: EXPERIMENTAL
Intervention: Community innovations
Number of subjects: 12
Study 37406180 — intervention group
Group type: EXPERIMENTAL
Intervention: Key success factors
Number of subjects: 12
Study 37406180 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenges faced
Number of subjects: 12
Study 37406251 — intervention group
Group type: EXPERIMENTAL
Intervention: Somapacitan (0.16 mg/kg/wk)
Number of subjects: 200
Study 37406251 — intervention group
Group type: COMPARATOR
Intervention: Daily GH (0.034 mg/kg/d)
Number of subjects: 200
Study 37406251 — intervention group
Group type: EXPERIMENTAL
Intervention: Somapacitan
Number of subjects: 200
Study 37406350 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline set 1 (GS1) - 2018 ASCO/CAP guidelines for breast cancer
Number of subjects: 43
Study 37406350 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline set 2 (GS2) - recent proposal modifying enrollment criteria for clinical trial NCT01367002
Number of subjects: 43
Study 37406350 — intervention group
Group type: COMPARATOR
Intervention: Both GS1 and GS2
Number of subjects: 43
Study 37406350 — intervention group
Group type: EXPERIMENTAL
Intervention: GS1
Number of subjects: 43
Study 37406350 — intervention group
Group type: EXPERIMENTAL
Intervention: GS2
Number of subjects: 43
Study 37406374 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Number of subjects: 139
Study 37406374 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 139
Study 37406462 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal CPAP
Number of subjects: 109
Study 37406462 — intervention group
Group type: COMPARATOR
Intervention: Simple face mask
Number of subjects: 109
Study 37406760 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-arrest diagnosis of pulmonary hypertension (PH)
Number of subjects: 1129
Study 37406769 — intervention group
Group type: EXPERIMENTAL
Intervention: High 1000 mg daily prenatal DHA supplement
Number of subjects: 0
Study 37406769 — intervention group
Group type: COMPARATOR
Intervention: Low 200 mg daily prenatal DHA supplement
Number of subjects: 0
Study 37406777 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of VLA2001
Number of subjects: 958
Study 37406777 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of VLA2001 in VLA2001-primed participants
Number of subjects: 958
Study 37406777 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of VLA2001 in ChAdOx1-S-primed participants
Number of subjects: 958
Study 37406924 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-week rehabilitation program (RP)
Number of subjects: 25
Study 37406924 — intervention group
Group type: COMPARATOR
Intervention: 9-week control period without intervention
Number of subjects: 25
Study 37407001 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Number of subjects: 317
Study 37407040 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium Soft Chew D3 and a multivitamin supplement (MVS) specifically developed according to the type of operation; oesophagectomy group receives Multi-E, gastrectomy group receives Multi-G. MVSs taken once daily, Calcium Soft Chew D3 two times per day.
Number of subjects: 248
Study 37407045 — intervention group
Group type: EXPERIMENTAL
Intervention: Deliberative engagement through an online forum discussion
Number of subjects: 31
Study 37407049 — intervention group
Group type: EXPERIMENTAL
Intervention: Food intake as assessed by a web-based Food Frequency Questionnaire
Number of subjects: 4000
Study 37407055 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat
Number of subjects: 0
Study 37407055 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37407058 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Peer Navigator (FPN)
Number of subjects: 40
Study 37407058 — intervention group
Group type: COMPARATOR
Intervention: Low-intensive care coordination
Number of subjects: 40
Study 37407059 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory approach interventions developed by students, parents, teachers, and community stakeholders in intervention schools.
Number of subjects: 3153
Study 37407059 — intervention group
Group type: COMPARATOR
Intervention: Global School-based Student Health Survey (GSHS) administered to students.
Number of subjects: 3153
Study 37407059 — intervention group
Group type: COMPARATOR
Intervention: Validation of GSHS physical activity questions against wrist-worn accelerometry in control schools.
Number of subjects: 3153
Study 37407096 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital cognitive behavioural therapy for insomnia (n=48)
Number of subjects: 86
Study 37407096 — intervention group
Group type: COMPARATOR
Intervention: Control (sleep hygiene information, n=36)
Number of subjects: 86
Study 37407110 — intervention group
Group type: EXPERIMENTAL
Intervention: SAPIEN 3 Transcatheter Aortic Valve Replacement (TAVR)
Number of subjects: 783
Study 37407110 — intervention group
Group type: COMPARATOR
Intervention: Surgical Aortic Valve Replacement (SAVR)
Number of subjects: 783
Study 37407113 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 3123
Study 37407113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3123
Study 37407142 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib plus EsPhALL chemotherapy
Number of subjects: 106
Study 37407142 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 106
Study 37407142 — intervention group
Group type: COMPARATOR
Intervention: Imatinib plus chemotherapy
Number of subjects: 106
Study 37407154 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 8239
Study 37407154 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 8239
Study 37407274 — intervention group
Group type: EXPERIMENTAL
Intervention: PLD with conventional chemotherapy
Number of subjects: 8277
Study 37407274 — intervention group
Group type: COMPARATOR
Intervention: PLD with another chemotherapy agent
Number of subjects: 8277
Study 37407274 — intervention group
Group type: EXPERIMENTAL
Intervention: PLD with chemotherapy
Number of subjects: 8277
Study 37407274 — intervention group
Group type: COMPARATOR
Intervention: PLD alone
Number of subjects: 8277
Study 37407279 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooled radiofrequency ablation
Number of subjects: 210
Study 37407279 — intervention group
Group type: COMPARATOR
Intervention: Standard medical management
Number of subjects: 210
Study 37407326 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2D6 genotype-guided metoprolol administration
Number of subjects: 73
Study 37407326 — intervention group
Group type: COMPARATOR
Intervention: Historical reference incidence
Number of subjects: 73
Study 37407326 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2D6 genotype-guided metoprolol management
Number of subjects: 73
Study 37407386 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower BMI
Number of subjects: 79
Study 37407386 — intervention group
Group type: COMPARATOR
Intervention: BMI
Number of subjects: 79
Study 37407487 — intervention group
Group type: EXPERIMENTAL
Intervention: Improving TMPFC group (n=11; 4.7%)
Number of subjects: 235
Study 37407487 — intervention group
Group type: COMPARATOR
Intervention: Stable TMPFC group (n=182; 77.4%)
Number of subjects: 235
Study 37407487 — intervention group
Group type: COMPARATOR
Intervention: Worsening TMPFC group (n=42; 17.9%)
Number of subjects: 235
Study 37407711 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-immersive virtual reality (VR) distraction video
Number of subjects: 122